0JV0 Stock Overview
A preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
iBio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.51 |
| 52 Week High | US$46.76 |
| 52 Week Low | US$3.51 |
| Beta | -3.84 |
| 1 Month Change | 0% |
| 3 Month Change | -0.17% |
| 1 Year Change | -84.45% |
| 3 Year Change | -99.54% |
| 5 Year Change | -99.05% |
| Change since IPO | -99.93% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0JV0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 1.1% | 3.4% |
| 1Y | -84.4% | -14.9% | 15.0% |
Return vs Industry: 0JV0 underperformed the German Biotechs industry which returned -23.5% over the past year.
Return vs Market: 0JV0 underperformed the German Market which returned 1% over the past year.
Price Volatility
| 0JV0 volatility | |
|---|---|
| 0JV0 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in DE Market | 12.9% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: 0JV0's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 0JV0's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 26 | Martin Brenner | ibioinc.com |
iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever.
iBio, Inc. Fundamentals Summary
| 0JV0 fundamental statistics | |
|---|---|
| Market cap | €3.82m |
| Earnings (TTM) | -€19.13m |
| Revenue (TTM) | €46.06k |
82.9x
P/S Ratio-0.2x
P/E RatioIs 0JV0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0JV0 income statement (TTM) | |
|---|---|
| Revenue | US$50.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$50.00k |
| Other Expenses | US$20.82m |
| Earnings | -US$20.77m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.96 |
| Gross Margin | 100.00% |
| Net Profit Margin | -41,546.00% |
| Debt/Equity Ratio | 142.8% |
How did 0JV0 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/02/27 23:59 |
| End of Day Share Price | 2023/11/30 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
iBio, Inc. is covered by 6 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Kemp Dolliver | Brookline Capital Markets |
| Keay Nakae | Chardan Capital Markets, LLC |
| Douglas Buchanan | Citizens JMP Securities, LLC |